Cargando…

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea

INTRODUCTION: Trivalent influenza vaccines (TIVs) are currently reimbursed for subjects aged ≥ 65 years and children between 6 and 59 months of age under a national immunization program in South Korea. Quadrivalent influenza vaccines (QIVs) are expected to address the potential problem of influenza...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yun-Kyung, Song, Joon Young, Jang, Hyeongap, Kim, Tae Hyun, Koo, Heejo, Varghese, Lijoy, Han, Euna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244612/ https://www.ncbi.nlm.nih.gov/pubmed/30251078 http://dx.doi.org/10.1007/s40273-018-0715-5

Ejemplares similares

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
por: You, Joyce HS, et al.
Publicado: (2014)

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
por: Nagy, Lisa, et al.
Publicado: (2016)

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia
por: de Boer, Pieter T., et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2018)

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
por: Bianculli, Pablo Manuel, et al.
Publicado: (2022)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model
por: Rudenko, Larisa, et al.
Publicado: (2018)

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Factors affecting influenza vaccination in adults aged 50-64 years with high-risk chronic diseases in South Korea
por: Jang, Hyeongap, et al.
Publicado: (2019)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
por: Dolk, Christiaan, et al.
Publicado: (2016)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach
por: Brogan, Anita J., et al.
Publicado: (2016)

Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil – comparison of outcomes from different static model types
por: Van Bellinghen, Laure-Anne, et al.
Publicado: (2018)

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years
por: Domachowske, Joseph B., et al.
Publicado: (2013)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6–35 Months
por: Lee, Jee Hyun, et al.
Publicado: (2019)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study
por: Milne, George J., et al.
Publicado: (2016)

From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
por: Crépey, Pascal, et al.
Publicado: (2020)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
por: Jamotte, Aurélien, et al.
Publicado: (2016)

Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2019)

Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017
por: Gaglani, Manjusha, et al.
Publicado: (2020)

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2022)

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay
por: Arbo, Antonio, et al.
Publicado: (2022)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia
por: Aljunid, Syed Mohamed, et al.
Publicado: (2023)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
por: Liu, Xiaoqiang, et al.
Publicado: (2022)

989. Clinical Effectiveness of High-Dose Trivalent vs. Quadrivalent Influenza Vaccination Among Veterans Health Administration Patients
por: Young-Xu, Yinong, et al.
Publicado: (2018)

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2023)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4tp06hfaapl6e098mb7ptarqdt